panitumumab

Trials studying panitumumab

• phase1Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancernot yet recruitingn=136
• phase2A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancerrecruitingn=150
• phase2A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancerrecruitingn=390
• phase2Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutationterminatedn=3
• phase3Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutationrecruitingn=450
• phase1A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumorsrecruitingn=364
• phase1A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRIrecruitingn=180
• phase2Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Canceractive not recruitingn=42